Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BERKELEY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2023 and reviewed recent pipeline progress.
- “For our lead program, CB-010, we plan to present initial dose expansion data and the RP2D in the second quarter of 2024.
- For our third program, CB-012, we are thrilled to have recently dosed the first patient in the AMpLify trial.
- In December 2023, Caribou shared regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B clinical meeting.
- CB-012: Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.